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Next-generation sequencing (NGS) technologies have greatly impacted on every field of molecular research mainly because they
reduce costs and increase throughput of DNA sequencing. These features, together with the technology’s flexibility, have opened
the way to a variety of applications including the study of the molecular basis of human diseases. Several analytical approaches
have been developed to selectively enrich regions of interest from the whole genome in order to identify germinal and/or somatic
sequence variants and to studyDNAmethylation.These approaches are nowwidely used in research, and they are already being used
in routine molecular diagnostics. However, some issues are still controversial, namely, standardization of methods, data analysis
and storage, and ethical aspects. Besides providing an overview of the NGS-based approaches most frequently used to study the
molecular basis of human diseases at DNA level, we discuss the principal challenges and applications of NGS in the field of human
genomics.
1. Introduction
DNA sequencing is the process of determining the exact
order of the nucleotides in a DNA segment, corresponding
to single gene(s) or to a variety of molecules in the case of
the whole genome, or a large part of it. Therefore, techniques
able to do this have radically changed the course of molecular
research in all its fields of application. In the last 30 years,
the so-called Sanger sequencing has been the most widely
used sequencing technology worldwide [1]. Its use peaked
with the human genome project, which, in 2001, elucidated
the entire human genome [2, 3]. Although Sanger sequencing
is now completely automated, it is a method based on one
or more amplicons that sequence relatively small strings
of DNA rather than a complete gene or a set of genes in
the human genome. Consequently, it is an expensive and
time-consuming procedure if used to determine the entire
chromosomal asset of a single organ tissue, or even cell.
In the last ten years, novel technologies, collectively called
“next-generation sequencing” (NGS), have become available
and have dramatically increased the throughput of DNA
sequencing, thereby simultaneously reducing its costs [4].
Just to give an idea of what this means, it took more than 10
years to elucidate the first human genome sequence and it cost
USD 3 billion. Using NGS instruments, the entire genome
sequence of an individual can now be elucidated in less than
1 year and at a much lower cost [5]. It is expected that the
sequencing of the entire genome of an individual will soon
cost a few thousand USD (now 2,000USD/genome without
interpretation) [6].
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These advances in genomic technologies have accelerated
the search for genetic causes of human diseases and have
enabled investigators to answer previously unapproachable
questions about disease pathogenesis. In recent years, several
NGS-based approaches have been devised and validated to
facilitate the study of the molecular basis of human diseases
[6]. The ultimate aims are (i) to develop novel, sensitive,
accurate, and cost- and time-effective pipelines for molecular
diagnostics and (ii) to elucidate the mechanisms involved
in disease development and so to identify novel diagnostic,
prognostic, and therapeutic markers [7]. In fact, NGS tech-
nologies can be easily applied to a wide range of research
fields; thus far, they have been successfully used to analyze
target regions of the human genome ranging in size from
the entire exome to a restricted number of genes or a single
amplicon [8–10]. In addition to the detection of nucleotide
variants on DNA regions, NGS-based strategies can shed
light on the DNAmethylation status, at both single gene and
genome-wide level [11]. Importantly, apart from the human
genome, NGS gave immeasurable impetus to metagenomics.
In fact, work based on NGS revealed the complexity of the
microbiota not only in diverse tissues and organs, but also in
relation to a variety of physiological conditions (e.g., sex, age,
and circadian rhythm) as well as in pathological conditions
[12].
NovelNGS-based strategies are continuously being devel-
oped and it is conceivable that these technologies will become
even more routine also for diagnostic purposes, particularly
in view of the progressive simplification ofNGSprotocols, the
reduction in the operator’s “hands on” work, and the launch
of the “benchtop” NGS platforms. Notably, the integration of
data obtained using several NGS-based strategies could shed
light on the mechanisms involved in disease development
and, in turn, reveal targets that can be manipulated to obtain
better identification, stratification, and treatment of patients.
Here, we review the main NGS-based approaches cur-
rently used to study the molecular basis of human diseases
at DNA level and discuss the main advantages, principal
applications, and possible limitations of each.
2. NGS-Based Analytic Approaches for
the Study of Human Diseases
2.1. Identification of DNA Sequence Variants. The study of
entire genomes is faster and cheaper with NGS techniques
than with conventional Sanger sequencing [13, 14]. However,
the entire sequencing of a large number of samples is not yet
feasible for routine use due to the cost, time, and infrastruc-
tures required. Consequently, various approaches to specif-
ically enrich target genomic regions simultaneously thereby
allowing barcoding of samples for sequence multiplexing
have been developed and can be divided into polymerase
chain reaction- (PCR-) based and non-PCR-based strategies.
Both strategies can be used for NGS library preparation; the
choice of the most appropriate strategy depends on the size
of the target regions, the number of samples to be analyzed,
the cost and time required, and the biological questions to
be addressed, as reviewed in the following subsections. The
specific analytic features and applications to human diseases
of each of these approaches are summarized in Tables 1 and
2, respectively.
2.1.1. PCR-Based Strategies. PCR-based strategies have been
the most widely used presequencing strategies since they
are perfectly compatible with Sanger sequencing and also
with all NGS methodologies and instruments: the amplicons
resulting from amplification have NGS-platform-specific
adapters ligated to their ends. These represent a library that
is suitable for downstream sequencing reactions [8]. Since
barcode sequence tags can be added during this step, sample
multiplexing is possible [15]. Amplicon sequencing refers
to ultradeep sequencing of PCR products obtained from
one or several specific targets in order to determine, for
example, genetic variations contained in precise portions of
the genome. However, PCR amplification is too laborious for
large-scale NGS downstream applications and risks being a
bottleneck in the sample preparationworkflow; consequently,
more appropriate PCR procedures were developed. Below
we briefly review long-range PCR, multiplex PCR, and
microdroplet PCR [16–18].
Long-Range PCR. Long-range PCR procedures can be used to
analyze up to several hundreds of kilobases (kb), such as the
entire sequence of a single gene of interest. This enrichment
strategy requires the design of large overlapping amplicons
ranging in size from 2 to 12 kb. Each amplicon must be
individually amplified, purified, and quantified. Then, all
amplicons from the same sample can be pooled in equimolar
amounts and used to obtain a library obtained using shotgun
protocols. Since barcoded adapters can be added to the
mixture in this step, sample multiplexing is allowed.
Long-range PCR has been used to obtain a compre-
hensive genetic map of a specific genomic locus, 136 kb on
chr8q24, which is related to an increased risk of prostate and
colon cancer [16]. The same strategy has been successfully
used for the complete sequence analysis of large genes such
as dystrophin, BRCA1, and BRCA2 [19, 20]. Although long-
range PCR can be used to analyze an entire gene of interest
including introns, the promoter, and the 3󸀠 untranslated
regions (UTR), it has some limitations. Long PCRs require
high fidelity Taq polymerase, and amplifications conditions
could require a long optimization time. Therefore, this
approach is not suitable for large-scale applications and
should be limited to the analysis of single genes.
Multiplex PCR. Multiplex PCR is a PCR improvement that
enables the simultaneous analysis of multiple targets. In this
case, amplicons of different sizes are amplified in one or
more multiplex mixtures. Next, a nested PCR is carried out
for adapter ligation and amplicon barcoding; all reactions
from the same sample are pooled to obtain a multiple
amplicon library/sample so that several tagged libraries can
be sequenced together.
Multiplex PCR is especially suitable for the simultaneous
sequencing of 15 and even more exons, in one or more genes
of interest, which results in significant savings in terms of
time and costs. Indeed, by targeting multiple genes simulta-
neously, more comprehensive information can be obtained
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Table 2: Principal clinical applications of NGS technologies to the
study of the molecular basis of human diseases.
Clinical application NGS approaches
Variant detection
Long PCR [15, 18, 19]
Multiplex PCR [16, 20–30]
Microdroplet PCR [31, 32]
WES [47–50, 53–59, 67–75]
Targeted capture [86–88, 91–96]
WGS [110–112, 115–118]
Prenatal diagnosis WES [60, 64–70]Targeted capture [101]
Circulating tumor cells
analysis WES [80]
Pharmacogenomics
WES [81–83]
Targeted capture [97–99]
WGS [113, 114]
Gene expression regulation
Microdroplet PCR [38]
WG bisulfite sequencing
[132–139]
RNA-seq [156–162]
WES, whole-exome sequencing; WG, whole genome.
from a single test run. Notwithstanding these advantages,
multiplex PCR can be used only for the analysis of specific
known, not very large, carefully selected DNA regions, and
the efficiency of the procedure depends strictly on primer
design. Hence, time and costs increase in proportion to the
number of genes analyzed and their size.
Various commercial kits are available for multiplex PCR-
based enrichment. This approach has been used to study
the molecular basis of several inherited diseases, namely,
familial hypercholesterolemia [17], Alport syndrome [21],
hematologic malignancies [22, 23], and cystic fibrosis [24,
25]. It has been also used to identify both somatic and
germline mutations in cancer-related genes [26, 27]. Hansen
et al., for example, developed an amplicon-based sequencing
workflow for the analysis of four genes, predisposing to
colorectal cancer [28]. This approach has also been used for
themolecular analysis of the BRCAgenes [29–33]. Finally, Sie
et al. successfully used a multiplex PCR approach for somatic
mutation profiling [34].
Taken together, these data indicate that multiplex PCR-
based approaches are reliable in detecting mutations in small
targets and suggest they could be used in routine diagnostic
workflows thanks to their accuracy, speed, and cost-saving
features. One advantage of multiplex PCR-based methods
is the homogeneous distribution of amplicons, which in
turn results in a homogeneous distribution of sequencing
reads and a more uniform coverage. This is particularly
important when thesemethods are used in clinical diagnostic
procedures. In fact, in such cases, the entire target region
must be sequenced without leaving any small sequence gaps,
which might harbor the disease-causing mutation. In this
context, it is advisable to verify the presence and relative
abundance of the different amplicons using presequencing
fragment analysis protocols. This verification step not only
ensures a high sequence quality and a target coverage close
to 100% but also may detect deleterious mutations [35].
Microdroplet PCR. Microdroplet PCR is a target enrichment
procedure based on high throughputmultiplex amplification.
Each amplicon is amplified within a droplet of a water-in-
oil emulsion to prevent cross-contamination in the reaction
tube. Thus, while classical PCR is the amplification of one
amplicon in one reaction tube and multiplex PCR is the
amplification of a mixture of amplicons in the same reaction
tube, microdroplet PCR is the amplification of up to 20,000
different amplicons each inside its own droplet all of which
are collected in the same reaction tube. Droplets are gener-
ated by fully automated systems that use microfluidic sup-
ports (e.g., the RainDance ThunderStorm System). Primer
droplets, each containing just one primer pair, are produced
to specifically amplify each target of interest. In the same way,
each DNA molecule is eluted in a droplet together with the
amplification reaction mixture. Each of these two kinds of
droplets flows along their microfluidic channel to the merge
area, where they fuse into a single droplet that contains one
primer pair and one DNA molecule. All the droplets are
collected in a reaction tube and amplified before sequencing.
This approach can be used to enrich targets within the human
genome [18].
Microdroplet PCR has been applied in cancer [36] and
in inherited diseases such as congenital muscular dystrophy
[37]. In addition, it has been proposed for large-scale, targeted
bisulfite sequencing for methylation profiling [38]. Based
on the studies conducted so far, microdroplet technology
could be used to process DNA for the massively parallel
amplification of specific subsets of the human genome for
targeted sequencing. More evidence must be obtained before
microdroplet PCR can be applied for routine diagnostic
purposes.
2.1.2. Non-PCR-Based Strategies. The so-called “sequence
capture” approach, unlike PCR, is an excellent way to isolate
large or highly dispersed regions from a pool of DNA
molecules [39]. Sequence capture is essentially based on
hybrid capture reactions for the selective enrichment of
targeted genomic regions. Specific capture probes can be
synthesized to enrich the regions of interest from the whole
genome, thus obtaining a captured, adapted, and barcoded
library for NGS applications [9, 40, 41]. In detail, DNA
fragments hybridize to the capture probes synthesized on
DNA microarray glass slides in array-based hybridization
[9], whereas biotinylated DNA or RNA probes are used in
liquid-phase hybridization.The nontargeted DNA fragments
arewashed away and the enrichedDNA is recovered and used
for high throughput sequencing. Currently, threemajor com-
mercial products, namely, Nimblegen’s SeqCap (array-based
and solution-based), Illumina’s TruSeq (solution-based), and
Agilent’s Sure-Select (array-based and solution-based), are
used in combination with NGS platforms (e.g., Illumina,
Roche 454, and Solid) to achieve efficient target enrichment.
In addition to these, the HaloPlex technology from Agilent
(solution-based) is a well-known example of an enrichment
system featuring a selective circularization-based method
that is a further development of the principle of selector
probes used in several diagnostic approaches [42, 43].
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Although PCR-based enrichment methods have the ben-
efit of even coverage and high specificity, in some cases DNA
sequence capture is to be preferred because hybridization is
less sensitive to contamination and the procedure is less vul-
nerable to mismatches. In addition, PCR specificity depends
on reaction optimization and primer design: large rear-
rangements in genomes, for example, may be undetectable.
Unlike PCR, hybridization capture requires relatively large
amounts of high-quality DNA and target molecules may be
lost during library preparation. Therefore, this approach is
more suitable for the study of large genomic regions, either
contiguous or not contiguous, including the entire exome, as
discussed in greater detail under “Whole-Exome Sequencing”
and “Targeted DNA Sequence Capture Sequencing” below.
Whole-Exome Sequencing. Whole-exome sequencing (WES)
serves to selectively sequence the coding regions of a genome
in order to discover rare or common variants associated with
a disorder or phenotype [44, 45]. In humans, the exome
represents approximately 1% (30 megabases (Mb)) of the
genome and it accounts for over 85% of disease-causing
mutations [10, 46]. Consequently, WES is an attractive and
practical approach for the study of coding variants related to
rare Mendelian disorders and of many disease-predisposing
single nucleotide polymorphisms throughout the exome [47].
Various target enrichment strategies are used in exome
sequencing to pull out the coding regions from the whole
genome, namely, array-based technologies, multiplex PCR,
selector probe (HaloPlex), solution hybridization (Illumina
TruSeq, Agilent SureSelect, andNimbleGen SeqCap EZ), and
molecular-inversion probes (MIPs) [47–50]. Each approach
has its capture efficiency and the choice of one approach over
another depends mainly on the researcher’s preference and
needs [51, 52].
The last few years has seen an exponential growth inWES
studies. This technique has been successfully used to identify
the causative variations in such heterogeneous conditions
as hearing loss [53–57], monogenic types of diabetes [58,
59], nonsyndromic mental retardation [60], and lysosomal
disorders [61]. In addition,WES has become a tool in routine
clinical practice [62]. One example is the case reported by
Choi et al. in 2009 [63] of a patient supposedly affected
by Bartter syndrome, a recessive renal tubular disorder
characterized by hypokalemia and hypochloremia, who car-
ried a novel homozygous mutation in the SLC26A3 gene
that is known to cause congenital chloride-losing diarrhea.
Therefore, the patient underwent a clinical reevaluation that
led to a final diagnosis of congenital chloride-losing diarrhea.
An exciting new application of WES is in the prenatal
diagnosis of aneuploidies. Fetal DNA can be extracted from
the plasma fraction of maternal peripheral blood thereby
avoiding an invasive approach [64–69]. A very recent paper
published in the New England Journal of Medicine showed
that prenatal testing on plasma-cell free DNA had signifi-
cantly lower false positive rates and higher positive predictive
values in detecting trisomies 21 and 18 than standard screen-
ing [70].
Yet another field of WES application is in cancer genetic
research. Human cancer is characterized by the accumulation
of genetic alterations andWES is an optimal tool for multiple
gene testing. For example, in the field of the molecular
genetics of cancer, WES has been applied in gastric cancer
[71, 72], lymphomas [73, 74], breast cancer [75], melanomas
[76, 77], and prostate cancer [78, 79]. Recently, WES was
used to study circulating tumor cells in metastatic prostate
cancer and revealed, with high accuracy, single nucleotide
variants that can potentially track tumor evolution, guide
therapy, and monitor relapses [80]. Cost-effective targeted
WES methods have also resulted in a step forward in the
field of personalized chemotherapy [81] and are now being
used in the fields of pharmacogenetics and personalized
medicine in general to identify inherited genetic variants able
to predict individual responses to specific treatment. In fact,
Daneshjou et al. [82] sequenced the entire exome of about 100
individuals and identified the genetic factors associated with
the response to different doses of warfarin. More recently,
usingWES, Apella´niz-Ruiz et al. [83] identified rare CYP3A4
variants associatedwith individual susceptibility to toxicity to
paclitaxel, which is a frequently used chemotherapy agent.
To sum up, WES has many strengths: it is less expensive
than whole-genome sequencing (WGS) (one exome costs
USD 1,000 whereas one genome costs around USD 2,000)
[6], it is an efficient strategy with which to identify the
genetic basis that underlies rare Mendelian disorders, and it
provides a small dataset compared to WGS and is thus easier
to interpret. On the other hand, exome sequencing obviously
analyzes only about one percent of the entire genome and
leaves out noncoding regions, such as untranslated regions
(5󸀠UTR and 3󸀠UTR), promoters, and other potentially func-
tional regions. This limitation could be overcome by cus-
tomizing commercial exome capture kits according to the
researcher’s scientific needs. Other limitations and challenges
related toWES are genetic heterogeneity (where several genes
are associated with the same disorder), natural duplicated
sequences throughout the genome, andpathogenicmutations
located in noncoding genes, have corresponding pseudo-
genes, contain repetitive or high CG-rich regions, or are
within the mitochondrial genome which are not detected.
In addition, large deletions/duplications/rearrangements and
mosaicism may not be detected by WES.
Finally, hybridization methods like WES may show some
biases when analyzing repetitive regions versus PCR-based
enrichment strategies and may not be able to efficiently
enrich them. This uneven sequence coverage should be
carefully evaluated in the diagnostic context since it could
result in the loss of clinically relevant sequence variations
and, thus, in false-negative results. Recently, Patwardhan
et al. demonstrated that “augmented exome sequencing,”
which is designed to increase sequence coverage in medically
relevant regions and in difficult-to-sequence regions, was
more efficient in the clinical setting than otherWES strategies
[84].
Targeted DNA Sequence Capture Sequencing. Target enrich-
ment strategies enable the efficient and rapid querying of spe-
cific large genomic regions of interest. Using this approach,
one can isolate genomic regions in a library and thereby quan-
titate both germline and somatic variants. As mentioned in
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Section 2.1.2, various hybridization-based enrichment meth-
ods, either in solution or on array, have been developed
[85, 86]. Targeted enrichment-based approaches necessitate
the identification of the target regions of interest and appro-
priately designed probes because repeating elements and high
guanine-cytosine content hamper complete target coverage.
Repetitive elements and internal duplications thatmay lead to
cross-hybridization are usually removed with repeat-masked
methods [87]. Long oligo probes (>50 base pairs (bp)), gener-
ally based on information from web-based tools (e.g., UCSC,
Ensemble, and RefSeq Database), should be designed so as to
increase probe specificity. Enrichment reliability can be eval-
uated based on several parameters: sensitivity and specificity,
that is, the percentage of target bases that are represented by
sequence reads and the percentage of sequences that map to
the intended targets, respectively, uniformity of enrichment
results and reproducibility of sequencing runs. Enrichment is
considered good when more than 60% of reads map against
the target regions. In addition, high coverage (>30x–40x)
improves sequencing accuracy. Many enrichment protocols
have been tested to increase target enrichment efficiency [88].
Compared to WGS, targeted resequencing can yield a much
higher coverage of genomic regions and reduce the time and
cost of the analysis. Currently, Illumina sequencing seems
to dominate the sequencing market thanks to its lower cost
and the shorter time required to process a large number of
samples [51].
In terms of accuracy, Illumina sequencing provides a
good data backbone and overcomes the homopolymer errors
that occur with other sequencing technologies; consequently,
it performs better than other strategies in the coverage of
medically relevant DNA sequence variations [89, 90].
In conclusion, given the above and the fact that target
enrichment technologies are easy to use, thesemethodologies
lend themselves to the study of the molecular basis of genetic
diseases, for both research and diagnostic purposes.Thus far,
target enrichment-based strategies have been used to identify
nucleotide variants [91, 92] and to validate novel diagnostic
tools [93–96] and for drug resistance/sensitivity profiling
[97–99]. This method is useful for the study of complex
families with different genotype/phenotype correlations and
to identify at-risk subjects [100]. Finally, hybridization-based
targeted sequencing of single nucleotide polymorphism
loci in maternal plasma DNA is a promising noninvasive
approach to the prenatal diagnosis of fetal chromosomal
anomalies [101]. Targeted enrichment technologies can be
used to study not only monogenic and polygenic diseases
[102–106], but also mitochondrial diseases [107], somatic
mutations in tumors [108], and chromosomal anomalies
[109]. Importantly, in all these settings, the analysis can be
extended to the noncoding regions. Thus, although WES has
some limitations in terms of data analysis, management, and
interpretation, target capture enables the study of a more
restricted and personalized target genomic region, thereby
simplifying data analysis and reducing experimental time
and costs.
2.1.3. Whole-Genome Sequencing. In the previous sections,
we have reviewed the different analytical presequencing
strategies currently available for the enrichment of specific
genomic regions of interest (from PCR-based approaches to
WES) and able to identify gene sequence variations at DNA
level. Although not yet suitable for routine applications due
to costs, analytical time required, and the huge amounts of
data produced, WGS has some advantages over enrichment
strategies and is briefly discussed in this section.
Whole-genome sequencing means the sequencing of
the human genome in its totality. Therefore, it allows
greater sequencing coverage uniformity and can identify also
copy number variations, large insertions/deletions, and gene
fusions. In addition, WGS covers all the genomic noncoding
regions, including introns, promoters, UTRs, and regulatory
elements; thus, it can shed light on the molecular alterations
involved in specific diseases [110, 111]. Recently, Belkadi et
al. compared the performances of WES and WGS in 6
individuals and found that sequencing quality was better and
the detection rate of variant higher withWGS than withWES
[112].
Whole-genome sequencing has also been applied in the
fields of pharmacogenetics and pharmacogenomics [113]. For
example, Mizzi et al. analyzed 482 unrelated individuals and
identified several pharmacogene-related variants potentially
involved in a given individual’s response to treatment [114].
Notably, WGS-based approaches are effective tools for large
population-based studies. Nagasaki el al. sequenced about
1,000 Japanese individuals and obtained a large population-
specific dataset of DNA variants that is useful for epidemio-
logical evaluations [115].
Finally, WGS has been used also to study the molecular
basis of human diseases. A study involving 50 patients with
severe intellectual disability showed the potential of this
approach for the molecular diagnosis of complex diseases
that can be caused by diverse kinds of mutations, including
de novo mutations and copy number variants [116]. Whole-
genome sequencing in a patient affected by familial adeno-
matous polyposis revealed an APC mosaicism, suggesting
that WGS could be a powerful tool also in the detection of
genetic mosaicism related to disease onset [117]. TheWGS of
a large cohort of patients with early onset familial Alzheimer
disease revealed a disease-specific haplotype and a potential
disease-progression modifier [118]. Of course, we expect
that the number of studies designed to assess the power of
WGS will grow rapidly in the next few years. However, as
extensively reviewed elsewhere [110, 111], the applications of
WGS for diagnostic purposes are still at an embryonic stage
due to its costs and particularly due to problems associated
with data analysis, interpretation, and storage. However, it is
conceivable that as new bioinformatic pipelines forWGS data
handling and interpretation become available and sequencing
costs decrease, WGS will become the strategy of choice for
studies of DNA sequence alterations.
2.2. Genome-Wide DNA Methylation Analysis. DNA methy-
lation is one of the more stable and heritable epigenetic
marks and its dysregulation is associated with many human
diseases [119]. The human genome is highly methylated;
approximately 80% of cytosines in CpG dinucleotides are
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chemically modified [120]. The assays for identifying methy-
lated CpG dinucleotides in a genome vary in terms of
resolution and cost. Although PCR-based DNA methylation
approaches have several advantages [121], the ongoing rev-
olution in sequencing technology has opened the door to
whole-genome DNA methylation analysis at a single-base-
pair resolution. There are three main approaches to whole-
genome methylation studies: enzyme digestion [11, 122],
affinity enrichment [123–126], and bisulfite sequencing [127–
131].
It is difficult to compare these three approaches given
their complexity and diversity.The choice of themost suitable
method depends on the desired coverage, accuracy, and
resolution, as well as on the number of samples and the DNA
quality and quantity. In general, enzyme digestion and affinity
enrichment-based methods are low-resolution and essen-
tially qualitative. Instead, bisulfite sequencing approaches
have a higher resolution and provide quantitative estimates
ofmethylation [132, 133].Whole-genome bisulfite sequencing
can assess about 95% of all CpG sites in the genome; however,
high coverage (>500 million paired-end reads to achieve
∼30x coverage) and high DNA input (1–1.5 versus 0.2 micro-
grams (g)) are required [131]; here it should be noted that
Illumina’s new EpiGnome Methyl-Seq kit requires only 50–
100 nanograms (𝜇g) of genomic DNA. Incomplete bisulfite
conversion and differential PCR efficiency for methylated
versus unmethylated sequences are the main limitations of
bisulfite sequencing approaches. Recently, sequence capture
enrichment methods have been developed also for DNA
methylation assessment at a single base resolution (Nim-
blegen/Roche SeqCap Epi and Agilent MethylSeq). These
approaches are based on the same enrichment methodology
used to identify DNA sequence variations for the enrichment
of bisulfite-converted DNA. Also in this case, these methods
enable genome-wide capture of all the annotated CpG islands
and customized enrichment to study pathways of interest
[134].
Advances in genome-wide DNA methylation technology
have also resulted in new strategies for the timely identifi-
cation of novel diagnostic and prognostic biomarkers. For
example, Huang and colleagues identified functional DNA
methylation biomarkers predictive of the clinical outcome of
ovarian cancer [135]; Jero´nimo and colleagues showed that
the glutathione-S-transferase P1 gene is methylated in >90%
of prostate cancers [136]. Moreover, 70 genes were found to
be significantly hypermethylated in gastric cancer tissue com-
pared with those observed in normal tissue [137]. Ghosh and
coworkers usedwhole-genomeDNAmethylation profiling to
explore a potential association between parity and epigenetic
changes in breast tissue from women with early parity and
nulliparity.They identified six genes that are hypermethylated
in the parous group [138]. Furthermore, in a very recent
article, Warton and colleagues described a comprehensive
technical analysis of free cell DNA (fcDNA) isolation from
healthy subjects and enrichment of methylated sequences
followed by NGS [139]. Their findings provide further sup-
port that whole-genome analysis of even small amounts of
fcDNA can provide high-quality, validated genomic data that
strengthen the potential of the usefulness of the methylation
signature of fcDNA in clinical applications. The epigenomic
data and the discovery of a specific pattern of epigenomic
marks associated with specific functional regions have also
helped to clarify genotype-phenotype association data.
2.3. Metagenomics. Although metagenomics does not
include the study of human genes but focuses on the charac-
terization of microbial communities, namely, microbiota,
living in specific environments, such as skin or mucosal
districts, growing evidence implicates the human micro-
biome in the development of various diseases. Therefore, it
seems appropriate to mention this technique, although for
further details we refer readers to more specific reviews on
this topic [12, 140–142]. It is now well known that the human
microbiome is required for the maintenance of the healthy
status [143] and that microbial dysbiosis could play a role in
several diseases like diabetes, inflammatory bowel diseases,
obesity, and cancer [144–149]. So, the study of microbiome
composition (both qualitatively and quantitatively) could
clarify diseases pathogenesis and, in turn, pave the way
to the development of novel diagnostic, prognostic, and
therapeutic targets. This explains the great interest in the
field. NGS-based approaches have greatly impacted also
metagenomics, thereby providing a comprehensive view of
microbial communities.
As we reviewed elsewhere [150], 16S bacterial ribosomal
RNA (rRNA) characterization, obtained using NGS-based
strategies, is now the techniquemost widely used to study the
microbiome. It is an amplicon-basedmethod that uses bacte-
rial universal primers to amplify the entiremicrobiome in one
PCR reaction [151].The complexity ofmicrobial communities
is resolved after sequencing, specifically assigning each read
to a group of bacteria through specific bioinformatics tools.
Using this approach, we monitored the gut microbiome of a
patient with Crohn disease before and after nutritional ther-
apy and showed that this therapy was effective in restoring
gut microbiome dysbiosis [152]. The same strategy has been
recently used to characterize the esophageal microbiome in
eosinophilic esophagitis [153], the lung microbiome of cystic
fibrosis patients [154], and the subgingival microbiota in
different periodontal diseases [155], and other studies are
appearing almost daily. It is conceivable that future technical
advances (especially those related to data analysis tools and to
the availability of microbial community databases) will shed
light on the functions of the human microbiome and its role
in human diseases, andmetagenomics could be an integrative
means with which to study the molecular basis of human
diseases at DNA level.
2.4. RNA Sequencing. The key to the molecular basis of
human diseases and the genotype-phenotype relationship
lies in gene expression and the mechanisms that control
it. Consequently, genome-wide expression analyses are now
pivotal in genomics and biomedical research. RNA sequenc-
ing (RNA-seq) technologies are elucidating the mechanisms
that expand the genome’s coding capacity and are revolu-
tionizing the concept of gene expression regulation. RNA-
seq is gradually replacing microarrays in high throughput
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gene expression studies because it provides more quantita-
tively accurate measurements and also absolute transcript
abundance data [156, 157]. RNA-seq also detects annotated
transcripts as well as novel sequences, splice variants, exon
junctions, noncoding RNA [158], single nucleotide poly-
morphisms [159], and fusion genes [160]. Various RNA-seq
techniques are available, and the one to use depends on the
RNA species being investigated: (i) total RNA sequencing
(total RNA-seq) is a process that removes rRNAs and thus
captures a broader range of gene expression changes and
reveals novel transcripts in both coding and noncoding RNA
species; (ii) coding RNA sequencing (mRNA-seq) provides
information about poly-A tailed RNAs; and (iii) small RNAs
sequencing (small RNA-seq) is used to discover and analyze
novel microRNAs (miRNAs) and other small noncoding
RNAs.
Changes in the expression of coding genes are controlled
at multiple levels, from transcription to RNA processing and
translation. Interestingly, the abundance of a transcript is
directly modified by polymorphisms in regulatory elements
[161]. An important class of variants, called expression quan-
titative trait loci (eQTL), influences the expression level of
the gene in two ways (local or distant) [162, 163]. Genome-
wide association studies combined with RNA-seq analysis
can reveal the eQTL and can shed light on the mechanism
whereby gene variability controls gene expression.The devel-
opment of techniques based on the integration of these data
will help to understand putative causal links between DNA
variation and expression.
3. NGS Data Analysis and Storage
Data management and analysis pipelines, based on bioin-
formatics expertise and hardware infrastructures, have been
developed to manage the massive sets of data produced by
NGS. The analysis of NGS data is commonly based on three
main analytic steps [164, 165], which are usually implemented
via specific bioinformatic tools: (i) generation of sequences
and assignment of base quality scores; (ii) demultiplexing
(if necessary), read alignment, and variant calling; and (iii)
identification and interpretation of variants according to
guidelines [166]. Different scripts and/or pipelines are used
in this last step depending on the kind of application, the
type of samples sequenced, and the biological question to
be addressed. For example, specific tools are available for
metagenomics [167–169] and RNA-seq studies [170, 171].
Storage of the huge amount of data generated by NGS
is an important issue. The Centers for Disease Control
and Prevention (http://www.cdc.gov/clia/Resources/GetRM)
requires storage of analytic systems records and data reports
for at least 2 years [172]. However, given the rapid growth of
knowledge in this field, longer storage could be contemplated
for raw data files (e.g., fastq files) so that the primary
results can be regenerated and analyzed as more advanced
accurate techniques become available to verify the original
interpretation. Consequently, sequencing centers should be
equipped with powerful dedicated storage equipment: it has
been estimated that 3.2 terabytes is required for the backup of
200 exomes [173].These infrastructures may be beyond some
laboratories, especially small laboratories. Publicly accessible
clouds represent a possible solution to data storage, although,
in a clinical context, data privacy issues should be carefully
addressed [174].
4. Next-Generation Sequencing in
the Clinical Setting and Ethical Disclosures
As reviewed in the previous sections, several NGS-based
approaches are available to study the molecular bases of
human diseases at DNA (and also at RNA) level and are
now routinely used in clinical diagnostics [7, 110]. In essence,
single gene analysis (multiplex PCR or long PCR) should
be restricted to cases of low genetic heterogeneity; gene
panel screening (microdroplet PCR or targeted sequence
capture enrichment) should be preferred in case of highly
heterogeneous diseases and/or for the differential diagnosis
of very similar diseases, while WES and WGS should be
considered in case of a very complex/rare phenotype, when
de novomutations are suspected or in case of noninformative
results after the analysis of a panel of targeted genes [175].
The main issue concerning the clinical use of NGS-based
approaches is the huge amount of data produced and its
interpretation: the greater the genomic region analyzed, the
greater the number of variants of uncertain significance
identified. Another concern regards the so-called incidental
findings, that is, mutation(s) with a known pathogenicity
but not related to the medical condition for which the
test was requested. Notably, the issue as to whether or not
incidental findings should be communicated to the patient
is hotly debated. Of course, a carefully produced patient-
informed consent procedure should be part of pretest genetic
counseling to prepare the patient for such kinds of results and
ask for their concerns regarding the knowledge of the results.
5. Development of Next-Generation
Sequencing Technology
Next-generation technologies were launched on the mar-
ket about ten years ago and their history is characterized
by a continuous release of novel instruments that usually
feature an increased throughput/sequencing run [176]. The
sample preparation workflow is usually based on three main
steps: library preparation (achieved with different strate-
gies depending on the project, as discussed in Section 2),
library amplification, and high throughput sequencing. Each
instrument uses specific chemistry, which accounts for some
differences in sequencing accuracy and quality. The features
of specific NGS platforms have been extensively reviewed
and compared elsewhere, Illumina technology being themost
widely used procedure to date [89]. Here, we provide an
overview of the more recently developed technologies that
may undergo further improvements in the next few years and
possibly replace currently used platforms.
Pacific Biosciences has developed a NGS platform based
on the real-time sequencing of single molecules (SMRT)
during polymerization reactions. The DNA polymerase is
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immobilized on the bottomofmicroscope chambers: the four
phosphate-labelled nucleotides are eluted in the chambers
and the sequences are read in real-time since fluorescent
specific signals are recorded after incorporation of each
nucleotide [177]. This procedure avoids library amplification
and consequently reduces the risk of PCR artefacts.The latest
version of this instrument has 150,000 chambers each able to
sequence 55,000 reads/run with an average length of 20 kb
and a maximum throughput of 1 gigabase per chamber in a
four-hour run. The absence of clonal amplification, together
with the long read length, makes this technology appealing
for a variety of applications [178, 179]; however, the error rate
is still high [180].
Another promising single molecule sequencing meth-
od is the nanopore-based strategy developed by Oxford
Nanopore Technologies. It is based on a flow-cell containing
hundreds of microwells. Each microwell contains a mem-
brane with a nanopore through which an ionic current flows.
When a biological molecule (DNA, RNA, or protein) flows
through the pore, each nucleotide/amino acid results in a
specific current change that discriminates among them [181].
Oxford Nanopore Technologies has developed three scalable
instruments, including the MinION, a USB-device portable
sequencer able to generate up to 16,000 reads/run with a
maximum length of 60 kb and an average throughput of
90Mb in an 18-hour run. Also in this case, the error rate is
still too high for routine use. Finally, Complete Genomics has
launched a fully automated apparatus for large-scaleWES and
WGS currently available only as a service. The instrument
is based on Combinatorial Probe-Anchor Ligation chemistry
[182] and is designed to sequence up to 10,000 genomes per
year with a 50x coverage.
To overcome the limitations and drawbacks of currently
available NGS instruments in terms of productivity, speed,
cost, and accuracy, many other sequencers, based on diverse
technologies (microfluidics, electron microscopy, nanopore-
based strategies, and DNA transistor-based procedures), are
currently under development.Therefore, it is conceivable that
NGS will become a “routine” procedure in the not too distant
future.
6. Conclusions
Next-generation sequencing technologies and the various
associated procedures, together with the plethora of data
they have generated and continue to generate, prompt several
basic concepts. Many diseases, if not all, are characterized by
genetic changes and thus are related to DNA sequence vari-
ants that must be analyzed for their consequences. However,
not all these variants shed light on a given disease, since they
are not directly pathogenetic or they contribute only slightly
to the pathogenesis of the disease. Therefore, to address the
complexity of the link between DNA sequence variants and
human diseases, high throughputDNA sequencing should be
as rapid and inexpensive as possible. Moreover, the sequence
and bioinformatic strategies that are continuously emerging,
togetherwith the detection ofDNA sequence changes, should
also take account of DNA modifying processes, such as
methylation. In addition, going from DNA to RNA, NGS
has enabled researchers to mine the enormous amount of
quantitative and qualitative data buried in themyriad of regu-
latory sequence elements that have been discovered in recent
years, namely, miRNA, long noncoding RNA, small circular
RNA, nuclear RNA, and nucleolar RNA.Notwithstanding the
enormous potential of these methodologies, the procedures
and guidelines have yet to be standardized, which probably
reflects the continuous innovations that are being made in
this field.
Notably, in the clinical context, besides confirming a
disease or correlating a gene alteration to a given disease,
NGS has the potential to become the frontline analysis for
differential diagnosis among clinically confounding diseases.
Thus, gene sequence profiling may be able to discriminate
one disease from another, therefore enabling timely effective
therapy.
The easier and faster production of highly accurate
sequence data will certainly give impetus to what is now
called “personalized genome analysis.” Besides examining
nosographically established diseases that affect many people,
personalized genome analysis can help to understand, at
single individual level, the minute differences that can affect
the health status of each person, which, in turn, can lead to
the application of “personalized medicine.”
Another important area of research that has benefitted
from NGS technology is the development of target drugs,
namely, drugs or compounds that act as bullets able to strike
a precise target in a DNA sequence, or at a corresponding
protein level, in order to nullify or even to reverse the nucleic
sequence from the variant to the wild-type status. This newly
emerging technique of gene editing requires very accurate
DNA and RNA sequences in order to design the most
effective tools with which to revert the altered nucleotide into
the wild type. This is a very promising avenue of research,
provided the related ethical issues are overcome.
Finally, NGS-based approaches have greatly improved
our understanding of the molecular basis of human diseases
in a variety of ways that were unthinkable just a few years
ago. The challenge now is to resolve the outstanding issues
of standardization of procedures, the production and storage
of personal data, and other ethical aspects, which we suspect
will animate scientific and regulatory debates in the next few
years.
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